20 biggest launches of 2012 were led by Kalydeco and Xtandi

04/10/2013 | Genetic Engineering & Biotechnology News

Vertex Pharmaceuticals' Kalydeco, or ivacaftor, topped Genetic Engineering & Biotechnology News' list of best-selling drugs that were approved and commercialized last year based on 2012 sales figures. Kalydeco generated sales of $171.6 million. Medivation and Astellas Pharma's Xtandi, or enzalutamide, came in second with $71.5 million, followed by Pfizer's Inlyta, or axitinib, with $70.1 million. Rounding out the top five were Onyx Pharmaceuticals' Kyprolis, or carfilzomib, and Roche Holding's Perjeta, or pertuzumab. The list includes the dates of approval in the U.S. and/or Europe.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations